文献速递消化系统肿瘤支持与姑息治疗

不可切除腹膜间皮瘤的真实世界免疫治疗结局:法国经验

Real-world immunotherapy outcomes in unresectable peritoneal mesothelioma: A French experience.
PubMed 文献 · Eur J Cancer · 2025-10-20

该研究纳入2017至2024年法国两家中心的22例不可手术腹膜间皮瘤患者,接受含免疫检查点抑制剂方案。中位随访13.76个月,中位无进展生存期10.22个月,中位总生存期16.8个月,客观缓解率30%,3级毒性仅3例,支持ICI作为治疗选择。

要点

  • 不可切除腹膜间皮瘤中,含ICI方案中位PFS 10.22个月,中位OS 16.8个月。
  • 可评估患者客观缓解率30%,6个月疾病控制率55%。
  • BAP1状态与PFS或OS无显著差异,3级毒性3例,无4级毒性。

核心结论

  • 在该欧洲真实世界队列中,含ICI治疗的获益得到确认,应考虑作为这一罕见情况的治疗选择。

研究设计与样本

  • 回顾性真实世界研究,纳入2017至2024年法国两家中心的22例不可手术腹膜间皮瘤患者,接受含ICI方案(免疫治疗联合或不联合抗血管生成药物)。

主要发现

  • 中位随访13.76个月(95%CI 6.40-22.49),中位PFS为10.22个月(95%CI 4.82-15.87),中位OS为16.8个月(95%CI 6.46-37.73)。
  • 可评估患者13例(62%),客观缓解率为30%(95%CI 22%-50%)。
  • 全队列6个月疾病控制率为55%(95%CI 33%-74.5%),12个月为41%(95%CI 21.9%-63.04%)。
  • BAP1阳性与阴性肿瘤间PFS(p=0.73)或OS(p=0.16)无显著差异。
  • 3级毒性发生于3例患者,未报告4级毒性。

临床怎么用

  • 对于不可切除或腹膜外受累的腹膜间皮瘤,含ICI方案可作为后线治疗选择,尤其在一线铂类化疗后无标准方案时。
  • 治疗期间需监测免疫相关毒性,本队列3级毒性发生率较低。

局限性

  • 样本量小(22例),仅来自法国两家中心,为真实世界回顾性设计。
  • 可评估缓解的患者仅13例(62%),客观缓解率估计的置信区间较宽。
  • 中位随访时间较短(13.76个月),生存数据可能尚不成熟。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Peritoneal mesothelioma is a rare disease treated with curative approach- cytoreductive surgery and hyperthermic intraperitoneal chemotherapy -when resectable.In case of inoperable disease or extra-peritoneal involvement, the standard of care is based primarily on systemic chemotherapy. Platinum-based chemotherapy is used in the first-line setting, but no standard exists for subsequent lines.Peritoneal mesothelioma harbors a pro-inflammatory tumor microenvironment, making it potentially sensitive to immune checkpoint inhibitors (ICIs). PATIENTS AND METHODS: We included inoperable patients with peritoneal mesothelioma treated between 2017 and 2024 at two institutions in France, using ICIs-based treatments (immunotherapy with or without anti-angiogenic agents).The primary endpoints were progression-free survival (PFS) and overall survival (OS). RESULTS: A total of 22 patients with peritoneal mesothelioma were included.The median age at diagnosis was 57 years (IQR: 50-66);the majority had epithelioid histology (n = 17; 77 %).After a median follow-up of 13.76 months (95 % CI: 6.40-22.49),median Progression free survival(PFS) was 10.22 months (95 % CI: 4.82-15.87),median Overall Survival(OS) was 16.8 months (95 % CI: 6.46-37.73) No significant differences in PFS (p = 0.73) or OS (p = 0.16) were observed between BAP1-positive and BAP1-negative tumors.Among evaluable patients (n = 13, 62 %), the objective response rate was 30 % (95 % CI: 22 %-50 %).The disease control rate at 6 and 12 months for the entire cohort was:55 % (95 % CI: 33 %-74.5 %) at 6 months and 41 % (95 % CI: 21.9 %-63.04 %) at 12 months.Grade 3 toxicity occurred in 3 patients; no grade 4 toxicity was reported. CONCLUSION: The benefit of ICI-based treatment was confirmed in this European real-world cohort and should be considered as a treatment option in this rare setting.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Smolenschi C, Boileve A, Vaflard P, et al. Real-world immunotherapy outcomes in unresectable peritoneal mesothelioma: A French experience. Eur J Cancer. 2025. PMID: 41207181. doi:10.1016/j.ejca.2025.116066

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。